Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Shuhao Zhang
Observed name:
S. Zhang
Institution:
Junshi Biosciences (China)
Observed institution:
Junshi Biosciences (China)
ORCID:
0009-0007-4826-7942
Observed ORCID:
0009-0007-4826-7942
OpenAlex ID:
A5029317953
Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
·
Clinical Cancer Research
·
20
Supplementary Figure S2 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
Supplementary Figure S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
PDF
Supplementary Table S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
Supplementary Methods S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
PDF
Supplementary Figure S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
Supplementary Table S2 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
PDF
Data from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
Supplementary Figure S3 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
Data from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
Supplementary Table S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
2553 Development of a small molecule for treatment of castration resistant prostate cancer via androgen receptor and IL6/STAT3 pathways
2015
·
Y. Hua
, W. Azeem
, et al.
·
European Journal of Cancer
Show more works
View as search
Works count:
12
Citation count:
20
H-index:
1
I10-index:
1
Year
Topic
Type
